These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate. Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197 [TBL] [Abstract][Full Text] [Related]
3. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis. Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466 [TBL] [Abstract][Full Text] [Related]
4. Closing the Gap: Counting and Sizing of Particles Across Submicron Range by Flow Cytometry in Therapeutic Protein Products. Zhang L; Shi S; Antochshuk V J Pharm Sci; 2017 Nov; 106(11):3215-3221. PubMed ID: 28625725 [TBL] [Abstract][Full Text] [Related]
5. Comparative Evaluation of Two Methods for Preparative Fractionation of Proteinaceous Subvisible Particles--Differential Centrifugation and FACS. Boll B; Folzer E; Finkler C; Huwyler J; Mahler HC; Schmidt R; Koulov AV Pharm Res; 2015 Dec; 32(12):3952-64. PubMed ID: 26195006 [TBL] [Abstract][Full Text] [Related]
6. A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products. Hubert M; Yang DT; Kwok SC; Rios A; Das TK; Patel A; Wuchner K; Antochshuk V; Junge F; Bou-Assaf GM; Cao S; Saggu M; Montrond L; Afonina N; Kolhe P; Loladze V; Narhi L J Pharm Sci; 2020 Jan; 109(1):830-844. PubMed ID: 31647951 [TBL] [Abstract][Full Text] [Related]
7. A Platform for Preparing Homogeneous Proteinaceous Subvisible Particles With Distinct Morphologies. Schack MM; Møller EH; Carpenter JF; Rades T; Groenning M J Pharm Sci; 2018 Jul; 107(7):1842-1851. PubMed ID: 29574228 [TBL] [Abstract][Full Text] [Related]
11. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress. Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of Incremental Siliconization Levels on Soluble Aggregates, Submicron and Subvisible Particles in a Prefilled Syringe Product. Bai S; Landsman P; Spencer A; DeCollibus D; Vega F; Temel DB; Houde D; Henderson O; Brader ML J Pharm Sci; 2016 Jan; 105(1):50-63. PubMed ID: 26852839 [TBL] [Abstract][Full Text] [Related]
13. Separation, Characterization and Discriminant Analysis of Subvisible Particles in Biologics Formulations. Akhunzada ZS; Hubert M; Sahin E; Pratt J Curr Pharm Biotechnol; 2019; 20(3):232-244. PubMed ID: 30767738 [TBL] [Abstract][Full Text] [Related]
14. Quantitative Differentiation of Protein Aggregates From Other Subvisible Particles in Viscous Mixtures Through Holographic Characterization. Winters A; Cheong FC; Odete MA; Lumer J; Ruffner DB; Mishra KI; Grier DG; Philips LA J Pharm Sci; 2020 Aug; 109(8):2405-2412. PubMed ID: 32439328 [TBL] [Abstract][Full Text] [Related]
15. Quantification and characterization of micrometer and submicrometer subvisible particles in protein therapeutics by use of a suspended microchannel resonator. Patel AR; Lau D; Liu J Anal Chem; 2012 Aug; 84(15):6833-40. PubMed ID: 22794526 [TBL] [Abstract][Full Text] [Related]
16. Particle sizing methods for the detection of protein aggregates in biopharmaceuticals. Khodabandehloo A; Chen DD Bioanalysis; 2017 Feb; 9(3):313-326. PubMed ID: 28098491 [TBL] [Abstract][Full Text] [Related]
17. Characterization of Nanoparticle Tracking Analysis for Quantification and Sizing of Submicron Particles of Therapeutic Proteins. Zhou C; Krueger AB; Barnard JG; Qi W; Carpenter JF J Pharm Sci; 2015 Aug; 104(8):2441-50. PubMed ID: 26017684 [TBL] [Abstract][Full Text] [Related]
18. Characterization of Protein Particles in Therapeutic Formulations Using Imaging Flow Cytometry. Probst C; Zeng Y; Zhu RR J Pharm Sci; 2017 Aug; 106(8):1952-1960. PubMed ID: 28456724 [TBL] [Abstract][Full Text] [Related]
19. Determination of the Density of Protein Particles Using a Suspended Microchannel Resonator. Folzer E; Khan TA; Schmidt R; Finkler C; Huwyler J; Mahler HC; Koulov AV J Pharm Sci; 2015 Dec; 104(12):4034-4040. PubMed ID: 26344825 [TBL] [Abstract][Full Text] [Related]